Cargando…

Protocol paper: Multi-site, cluster-randomized clinical trial for optimizing functional outcomes of older cancer survivors after chemotherapy

BACKGROUND: Cancer survivors over the age of 65 have unique needs due to the higher prevalence of functional and cognitive impairment, comorbidities, geriatric syndromes, and greater need for social support after chemotherapy. In this study, we will evaluate whether a Geriatric Evaluation and Manage...

Descripción completa

Detalles Bibliográficos
Autores principales: Yilmaz, S., Janelsins, M.C., Flannery, M., Culakova, E., Wells, M., Lin, P.-J., Loh, K.P., Epstein, R., Kamen, C., Kleckner, A.S., Norton, S.A., Plumb, S., Alberti, S., Doyle, K., Porto, M., Weber, M., Dukelow, N., Magnuson, A., Kehoe, L.A., Nightingale, G., Jensen-Battaglia, M., Mustian, K.M., Mohile, S.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283231/
https://www.ncbi.nlm.nih.gov/pubmed/35292232
http://dx.doi.org/10.1016/j.jgo.2022.03.001
_version_ 1784747282721144832
author Yilmaz, S.
Janelsins, M.C.
Flannery, M.
Culakova, E.
Wells, M.
Lin, P.-J.
Loh, K.P.
Epstein, R.
Kamen, C.
Kleckner, A.S.
Norton, S.A.
Plumb, S.
Alberti, S.
Doyle, K.
Porto, M.
Weber, M.
Dukelow, N.
Magnuson, A.
Kehoe, L.A.
Nightingale, G.
Jensen-Battaglia, M.
Mustian, K.M.
Mohile, S.G.
author_facet Yilmaz, S.
Janelsins, M.C.
Flannery, M.
Culakova, E.
Wells, M.
Lin, P.-J.
Loh, K.P.
Epstein, R.
Kamen, C.
Kleckner, A.S.
Norton, S.A.
Plumb, S.
Alberti, S.
Doyle, K.
Porto, M.
Weber, M.
Dukelow, N.
Magnuson, A.
Kehoe, L.A.
Nightingale, G.
Jensen-Battaglia, M.
Mustian, K.M.
Mohile, S.G.
author_sort Yilmaz, S.
collection PubMed
description BACKGROUND: Cancer survivors over the age of 65 have unique needs due to the higher prevalence of functional and cognitive impairment, comorbidities, geriatric syndromes, and greater need for social support after chemotherapy. In this study, we will evaluate whether a Geriatric Evaluation and Management-Survivorship (GEMS) intervention improves functional outcomes important to older cancer survivors following chemotherapy. METHODS: A cluster-randomized trial will be conducted in approximately 30 community oncology practices affiliated with the University of Rochester Cancer Center (URCC) National Cancer Institute Community Oncology Research Program (NCORP) Research Base. Participating sites will be randomized to the GEMS intervention, which includes Advanced Practice Practitioner (APP)-directed geriatric evaluation and management (GEM), and Survivorship Health Education (SHE) that is combined with Exercise for Cancer Patients (EXCAP©®), or usual care. Cancer survivors will be recruited from community oncology practices (of participating oncology physicians and APPs) after the enrolled clinicians have consented and completed a baseline survey. We will enroll 780 cancer survivors aged 65 years and older who have completed curative-intent chemotherapy for a solid tumor malignancy within four weeks of study enrollment. Cancer survivors will be asked to choose one caregiver to also participate for a total up to 780 caregivers. The primary aim is to compare the effectiveness of GEMS for improving patient-reported physical function at six months. The secondary aim is to compare effectiveness of GEMS for improving patient-reported cognitive function at six months. Tertiary aims include comparing the effectiveness of GEMS for improving: 1) Patient-reported physical function at twelve months; 2) objectively assessed physical function at six and twelve months; and 3) patient-reported cognitive function at twelve months and objectively assessed cognitive function at six and twelve months. Exploratory health care aims include: 1) Survivor satisfaction with care, 2) APP communication with primary care physicians (PCPs), 3) completion of referral appointments, and 4) hospitalizations at six and twelve months. Exploratory caregiver aims include: 1) Caregiver distress; 2) caregiver quality of life; 3) caregiver burden; and 4) satisfaction with patient care at six and twelve months. DISCUSSION: If successful, GEMS would be an option for a standardized APP-led survivorship care intervention. TRIAL REGISTRATION: ClinicalTrials.gov NCT05006482, registered on August 9, 2021.
format Online
Article
Text
id pubmed-9283231
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-92832312022-07-15 Protocol paper: Multi-site, cluster-randomized clinical trial for optimizing functional outcomes of older cancer survivors after chemotherapy Yilmaz, S. Janelsins, M.C. Flannery, M. Culakova, E. Wells, M. Lin, P.-J. Loh, K.P. Epstein, R. Kamen, C. Kleckner, A.S. Norton, S.A. Plumb, S. Alberti, S. Doyle, K. Porto, M. Weber, M. Dukelow, N. Magnuson, A. Kehoe, L.A. Nightingale, G. Jensen-Battaglia, M. Mustian, K.M. Mohile, S.G. J Geriatr Oncol Article BACKGROUND: Cancer survivors over the age of 65 have unique needs due to the higher prevalence of functional and cognitive impairment, comorbidities, geriatric syndromes, and greater need for social support after chemotherapy. In this study, we will evaluate whether a Geriatric Evaluation and Management-Survivorship (GEMS) intervention improves functional outcomes important to older cancer survivors following chemotherapy. METHODS: A cluster-randomized trial will be conducted in approximately 30 community oncology practices affiliated with the University of Rochester Cancer Center (URCC) National Cancer Institute Community Oncology Research Program (NCORP) Research Base. Participating sites will be randomized to the GEMS intervention, which includes Advanced Practice Practitioner (APP)-directed geriatric evaluation and management (GEM), and Survivorship Health Education (SHE) that is combined with Exercise for Cancer Patients (EXCAP©®), or usual care. Cancer survivors will be recruited from community oncology practices (of participating oncology physicians and APPs) after the enrolled clinicians have consented and completed a baseline survey. We will enroll 780 cancer survivors aged 65 years and older who have completed curative-intent chemotherapy for a solid tumor malignancy within four weeks of study enrollment. Cancer survivors will be asked to choose one caregiver to also participate for a total up to 780 caregivers. The primary aim is to compare the effectiveness of GEMS for improving patient-reported physical function at six months. The secondary aim is to compare effectiveness of GEMS for improving patient-reported cognitive function at six months. Tertiary aims include comparing the effectiveness of GEMS for improving: 1) Patient-reported physical function at twelve months; 2) objectively assessed physical function at six and twelve months; and 3) patient-reported cognitive function at twelve months and objectively assessed cognitive function at six and twelve months. Exploratory health care aims include: 1) Survivor satisfaction with care, 2) APP communication with primary care physicians (PCPs), 3) completion of referral appointments, and 4) hospitalizations at six and twelve months. Exploratory caregiver aims include: 1) Caregiver distress; 2) caregiver quality of life; 3) caregiver burden; and 4) satisfaction with patient care at six and twelve months. DISCUSSION: If successful, GEMS would be an option for a standardized APP-led survivorship care intervention. TRIAL REGISTRATION: ClinicalTrials.gov NCT05006482, registered on August 9, 2021. 2022-07 2022-03-12 /pmc/articles/PMC9283231/ /pubmed/35292232 http://dx.doi.org/10.1016/j.jgo.2022.03.001 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Article
Yilmaz, S.
Janelsins, M.C.
Flannery, M.
Culakova, E.
Wells, M.
Lin, P.-J.
Loh, K.P.
Epstein, R.
Kamen, C.
Kleckner, A.S.
Norton, S.A.
Plumb, S.
Alberti, S.
Doyle, K.
Porto, M.
Weber, M.
Dukelow, N.
Magnuson, A.
Kehoe, L.A.
Nightingale, G.
Jensen-Battaglia, M.
Mustian, K.M.
Mohile, S.G.
Protocol paper: Multi-site, cluster-randomized clinical trial for optimizing functional outcomes of older cancer survivors after chemotherapy
title Protocol paper: Multi-site, cluster-randomized clinical trial for optimizing functional outcomes of older cancer survivors after chemotherapy
title_full Protocol paper: Multi-site, cluster-randomized clinical trial for optimizing functional outcomes of older cancer survivors after chemotherapy
title_fullStr Protocol paper: Multi-site, cluster-randomized clinical trial for optimizing functional outcomes of older cancer survivors after chemotherapy
title_full_unstemmed Protocol paper: Multi-site, cluster-randomized clinical trial for optimizing functional outcomes of older cancer survivors after chemotherapy
title_short Protocol paper: Multi-site, cluster-randomized clinical trial for optimizing functional outcomes of older cancer survivors after chemotherapy
title_sort protocol paper: multi-site, cluster-randomized clinical trial for optimizing functional outcomes of older cancer survivors after chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283231/
https://www.ncbi.nlm.nih.gov/pubmed/35292232
http://dx.doi.org/10.1016/j.jgo.2022.03.001
work_keys_str_mv AT yilmazs protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT janelsinsmc protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT flannerym protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT culakovae protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT wellsm protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT linpj protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT lohkp protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT epsteinr protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT kamenc protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT kleckneras protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT nortonsa protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT plumbs protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT albertis protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT doylek protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT portom protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT weberm protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT dukelown protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT magnusona protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT kehoela protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT nightingaleg protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT jensenbattagliam protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT mustiankm protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy
AT mohilesg protocolpapermultisiteclusterrandomizedclinicaltrialforoptimizingfunctionaloutcomesofoldercancersurvivorsafterchemotherapy